{"id":329271,"date":"2021-04-25T15:54:26","date_gmt":"2021-04-25T13:54:26","guid":{"rendered":"https:\/\/medizinonline.com\/rybelsus-semaglutide-as-the-worlds-first-and-only-oral-glp-1-analogue-2\/"},"modified":"2021-04-25T15:54:26","modified_gmt":"2021-04-25T13:54:26","slug":"rybelsus-semaglutide-as-the-worlds-first-and-only-oral-glp-1-analogue-2","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/rybelsus-semaglutide-as-the-worlds-first-and-only-oral-glp-1-analogue-2\/","title":{"rendered":"RYBELSUS\u00ae &#8211; Semaglutide as the world&#8217;s first and only oral GLP-1 analogue"},"content":{"rendered":"<p>People with type 2 diabetes have too little endogenous GLP-1 (glucagon-like peptide 1) or its effect is reduced. Semaglutide, which mimics natural GLP-1, can compensate for this.<sup>1,2<\/sup> It lowers blood glucose, supports weight loss and reduction of cardiovascular burden.<sup>1,2,*<\/sup> RYBELSUS\u00ae (Semaglutide) is approved in Switzerland as the world&#8217;s first and only oral GLP-1 analog for patients with inadequately controlled T2DM.<sup>1<\/sup><\/p>\n<p> <!--more--> <\/p>\n<p>When we eat, our intestines produce a substance called GLP-1. This stimulates the secretion of insulin in the pancreas in a glucose-dependent manner and inhibits that of glucagon. In addition, GLP-1 slows gastric emptying, increases the feeling of satiety and centrally regulates cravings. This prevents the blood sugar from rising too high.<\/p>\n<p>In patients with type 2 diabetes, too little GLP-1 is probably released or its effect is impaired, which increases the blood glucose level and subsequently also the long-term blood glucose value HbA1C. The latter is a risk factor for various secondary diseases.<\/p>\n<p><strong>Semaglutide &#8211; a modern and potent GLP-1 analogue<\/strong><\/p>\n<p>Semaglutide is a modern and potent GLP-1 analogue that mimics natural GLP-1.<sup>1,2<\/sup> The optimized active ingredient is degraded in a delayed manner, which prolongs its duration of action and opens up new application possibilities.<sup>4<\/sup> Semaglutide can do the following:<\/p>\n<ul>\n<li>It lowers elevated blood glucose in a glucose-dependent manner, thereby significantly lowering patients&#8217; HbA1C.<sup>1,2<\/sup><\/li>\n<li>By regulating the feeling of satiety and hunger, it can lead to weight loss.<sup>1,2,*<\/sup><\/li>\n<\/ul>\n<p>All of this helps patients with inadequately controlled type 2 diabetes and obesity (BMI \u2265 28) achieve their treatment goals and prevent microvascular and macrovascular sequelae thanks to Semaglutide.<sup>1,2,*<\/sup> For these patients, a reduction in their cardiovascular burden is of key importance (prevention of myocardial infarction, stroke, etc.).<sup>3<\/sup><\/p>\n<p>The PIONEER 6 clinical trial of the cardiovascular outcome of oral semaglutide demonstrated a numerically reduced cardiovascular risk (vs. placebo).<sup>1,5,*<\/sup><\/p>\n<p><strong>Semaglutide (RYBELSUS\u00ae) as the world&#8217;s first and only oral GLP-1 analogue<\/strong><\/p>\n<p>In diabetes therapy, a departure for new shores is now beginning. Since April 2020, RYBELSUS\u00ae has been approved by Swissmedic in Switzerland for patients with T2DM, as the world&#8217;s first and only oral GLP-1 analog. The good efficacy of Semaglutide is opened up to an even larger group of patients via the simple administration of RYBELSUS\u00ae: This allows a choice between a once-daily RYBELSUS\u00ae tablet and the once-weekly subcutaneous Ozempic\u00ae.<sup>1,2<\/sup> With RYBELSUS\u00ae , 7 out of 10 patients achieve a treatment target of HbA1C \u22647 %, with a sustained effect.<sup>1<\/sup> This and the consistent weight loss under RYBELSUS\u00ae is significantly better compared to other modern antidiabetic drugs.<sup>1,*,**<\/sup><\/p>\n<p>The individually tunable patient benefit enables the optimization of compliance and thus effective prevention of secondary diseases.<sup>6<\/sup><\/p>\n<p><img decoding=\"async\" alt=\"\" data-src=\"https:\/\/assets.medizinonline.com\/sites\/default\/files\/field\/images\/ozempic_rybelsus_grafik_de.jpeg\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\"><\/p>\n<p>* RYBELSUS\u00ae and Ozempic\u00ae are indicated for the treatment of inadequately controlled type 2 diabetes mellitus in addition to diet and exercise, but are not indicated for weight loss or reduction of cardiovascular events.<\/p>\n<p>** Clinical trials showed significantly better glycemic control (baseline HbA1C during study duration) and weight reduction (change in body weight during study duration) for semaglutide vs. placebo (PIONEER 8<sup>)1,7<\/sup>, vs. empagliflozin (PIONEER 2<sup>)1,8<\/sup>, vs. sitagliptin (PIONEER 3 and PIONEER 7<sup>)1,9,10,<\/sup> and vs. liraglutide (PIONEER 4)1<sup>,11<\/sup>.<\/p>\n<p><strong>Abbreviations: CVOT:<\/strong> cardiovascular outcome study; GLP-1: glucagon-like peptide 1; T2DM: type 2 diabetes.<\/p>\n<p><strong>References<\/strong><\/p>\n<div><span style=\"font-size:11px\">1. Rybelsus\u00ae <a href=\"https:\/\/assets.medizinonline.com\/sites\/default\/files\/kurzfachinformation_ozempic_rybelsus.pdf\">Professional Information<\/a>, www.swissmedicinfo.ch.<\/span><\/div>\n<div><span style=\"font-size:11px\">2. Ozempic\u00ae <a href=\"https:\/\/assets.medizinonline.com\/sites\/default\/files\/kurzfachinformation_ozempic_rybelsus.pdf\">SmPC<\/a>, www.swissmedicinfo.ch.<\/span><\/div>\n<div><span style=\"font-size:11px\">3rd SGED\/SSED Working Group. Recommendations of the Swiss Society of Endocrinology and Diabetology (SGED\/SSED) for the treatment of type 2 diabetes mellitus (2020). Status: January 23, 2020. Available at: <a href=\"https:\/\/www.sgedssed.ch\/fileadmin\/user_upload\/6_Diabetologie\/61_Empfehlungen_Facharzt\/2020_Swiss_Recomm_Medis_DE_def.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.sgedssed.ch\/fileadmin\/user_upload\/6_Diabetologie\/61_Empfehlungen_Facharzt\/-2020_Swiss_Recomm_Medis_DE_def.pdf,<\/a> last accessed 05\/2020.<\/span><\/div>\n<div><span style=\"font-size:11px\">4. Lau et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015; 58:7370-80.<\/span><\/div>\n<div><span style=\"font-size:11px\">5 Husain et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-51.<\/span><\/div>\n<div><span style=\"font-size:11px\">6. Polonsky et al. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13(2):144-9.<\/span><\/div>\n<div><span style=\"font-size:11px\">7. Zinman et al. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care. 2019;42(12):2262-71.<\/span><\/div>\n<div><span style=\"font-size:11px\">8. Rodbard et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019;42(12):2272-81.<\/span><\/div>\n<div><span style=\"font-size:11px\">9. Rosenstock et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019;321(15):1466-80.<\/span><\/div>\n<div><span style=\"font-size:11px\">10 Pieber et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528-39.<\/span><\/div>\n<div><span style=\"font-size:11px\">11 Pratley et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39-50.<\/span><\/div>\n<div>&nbsp;<\/div>\n<div><a href=\"https:\/\/assets.medizinonline.com\/sites\/default\/files\/kurzfachinformation_ozempic_rybelsus.pdf\">Short Subject Information<\/a><\/div>\n<div>Freigabenummer CH21RYB00148_03\/2021<\/div>\n","protected":false},"excerpt":{"rendered":"<p>People with type 2 diabetes have too little endogenous GLP-1 (glucagon-like peptide 1) or its effect is reduced. Semaglutide, which mimics natural GLP-1, can compensate for this.1,2 It lowers blood&hellip;<\/p>\n","protected":false},"author":12,"featured_media":107293,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Sponsored Content","footnotes":""},"category":[11384,11548],"tags":[],"powerkit_post_featured":[],"class_list":["post-329271","post","type-post","status-publish","format-standard","has-post-thumbnail","category-endocrinology-and-diabetology","category-rx-en","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-04 04:20:42","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":329274,"slug":"rybelsus-semaglutide-premier-et-unique-analogue-du-glp-1-par-voie-orale-au-monde-2","post_title":"RYBELSUS\u00ae - Semaglutide, premier et unique analogue du GLP-1 par voie orale au monde","href":"https:\/\/medizinonline.com\/fr\/rybelsus-semaglutide-premier-et-unique-analogue-du-glp-1-par-voie-orale-au-monde-2\/"},"it_IT":{"locale":"it_IT","id":329276,"slug":"rybelsus-semaglutide-il-primo-e-unico-analogo-orale-del-glp-1-al-mondo-2","post_title":"RYBELSUS\u00ae - Semaglutide, il primo e unico analogo orale del GLP-1 al mondo.","href":"https:\/\/medizinonline.com\/it\/rybelsus-semaglutide-il-primo-e-unico-analogo-orale-del-glp-1-al-mondo-2\/"},"pt_PT":{"locale":"pt_PT","id":329245,"slug":"rybelsus-semaglutide-como-o-primeiro-e-unico-analogo-oral-glp-1-do-mundo-2","post_title":"RYBELSUS\u00ae - Semaglutide como o primeiro e \u00fanico an\u00e1logo oral GLP-1 do mundo","href":"https:\/\/medizinonline.com\/pt-pt\/rybelsus-semaglutide-como-o-primeiro-e-unico-analogo-oral-glp-1-do-mundo-2\/"},"es_ES":{"locale":"es_ES","id":329252,"slug":"rybelsus-semaglutida-como-primer-y-unico-analogo-oral-de-glp-1-del-mundo-2","post_title":"RYBELSUS\u00ae - Semaglutida como primer y \u00fanico an\u00e1logo oral de GLP-1 del mundo","href":"https:\/\/medizinonline.com\/es\/rybelsus-semaglutida-como-primer-y-unico-analogo-oral-de-glp-1-del-mundo-2\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/329271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=329271"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/329271\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/107293"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=329271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=329271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=329271"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=329271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}